论文部分内容阅读
目的:观察以脂质体多柔比星为主的联合化疗方案治疗晚期乳腺癌的临床疗效及不良反应。方法:收集2011年1月—2014年12月43例复发/转移性乳腺癌患者,患者均给予脂质体多柔比星为主的联合方案治疗,脂质体多柔比星给药剂量30 mg/m2。合并抗肿瘤药物按常规方法给药。21~28 d为化疗1周期。至少化疗2个周期后评价疗效和不良反应。结果:全组43例患者可评价疗效和不良反应。其中,完全缓解1例,部分缓解14例,疾病稳定16例,疾病进展12例,客观有效率为34.9%,临床获益率72.1%,中位疾病进展时间4.5个月。主要不良反应为骨髓抑制、消化道反应、疲乏、肝功能损害及手足综合征等,未见明显的心脏毒性。结论:以脂质体多柔比星为主的联合化疗治疗晚期乳腺癌疗效较好,不良反应可以耐受。
Objective: To observe the clinical efficacy and adverse reactions of liposomal doxorubicin-based combination chemotherapy in the treatment of advanced breast cancer. METHODS: Forty-three patients with recurrent / metastatic breast cancer from January 2011 to December 2014 were enrolled in this study. Patients were given liposomal doxorubicin-based combination regimen. Dosage of liposomal doxorubicin mg / m2. Antitumor drugs are administered in the usual way. 21 ~ 28 d for the 1 cycle of chemotherapy. After at least two cycles of chemotherapy to evaluate the efficacy and adverse reactions. Results: The whole group of 43 patients can evaluate the efficacy and adverse reactions. Among them, complete remission in 1 case, partial remission in 14 cases, stable disease in 16 cases, disease progression in 12 cases, objective efficiency was 34.9%, clinical benefit rate was 72.1%, median disease progression time 4.5 months. The main adverse reactions were myelosuppression, gastrointestinal reaction, fatigue, liver dysfunction and hand-foot syndrome, and no obvious cardiotoxicity. Conclusion: The combination of liposomal doxorubicin-based chemotherapy in the treatment of advanced breast cancer has good efficacy and adverse reactions can be tolerated.